AsianScientist (Aug. 11, 2016) – US-based biopharmaceutical company Sorrento Therapeutics and South Korean-based biopharmaceutical company CHA Biotech will enter into a joint venture to develop natural killer cell therapies. CHA Biotech will initially own 51 percent of the joint venture while Sorrento will initially hold the remaining 49 percent.
The venture will develop and commercialize proprietary chimeric antigen receptor (CAR) modified cellular therapies based on CHA Biotech’s activated killer cell (AKC) technology and five of Sorrento’s CARs for all disease conditions, including oncology and infectious diseases.
The AKC technology utilizes proprietary methodologies for the generation of highly activated, patient-derived natural killer cells from 60 mL of peripheral blood. The expansion and activation process takes less than three weeks and yields sufficient cells for several treatment cycles.
The resulting AKC product can be cryopreserved as efficient freeze-thaw protocols have been established. Thus far, more than 1,000 AKC batches have been produced and used in ongoing clinical studies in Japan.
———
Source: Sorrento Therapautics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
